IP Library › Granted Patent US 12,422,440
Granted Patent B2
US 12,422,440 · App. 17/282,989 · Granted Sep 23, 2025

Newborn screening for primary immunodeficiencies, cystinosis, and Wilson disease

Inventors: Sihoun Hahn (Clyde Hill, WA); Sunhee Jung (Seattle, WA); Jeffrey Whiteaker (Seattle, WA); Troy Torgerson (Seattle, WA); Amanda Paulovich (Seattle, WA); Christopher Collins (Seattle, WA); Remwilyn Dayuha (Lynnwood, WA)
Assignees: Seattle Children's Hospital; Fred Hutchinson Cancer Research Center
G01N33/6893C07K16/2809G01N33/6848C07K2317/34C07K2317/565G01N2800/24G01N2800/60
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,422,440
App. No.
17/282,989
Granted
Sep 23, 2025
Kind
B2
Abstract

Newborn screening for primary immunodeficiencies, cystinosis, and Wilson disease is described. The newborn screening can detect these disorders from dried blood spots already routinely collected at the time of birth. Early detection of these disorders will greatly improve patient outcome as each of them can be fatal once symptoms emerge.

Claims (68)

1. A method of detecting signature peptides of severe combined immunodeficiency (SCID), Wiskott-Aldrich syndrome (WAS), and/or X-linked agammaglobulinemia (XLA) in a dried blood spot (DBS) sample, the method comprising: obtaining a DBS sample; digesting proteins from the DBS sample with an enzyme to yield a digested DBS sample comprising peptides; enriching for:

a CD3ε signature peptide of SCID having the sequence of SEQ ID NO: 1 with an antibody or antigen-binding fragment thereof that binds the CD3ε signature peptide and comprises: a heavy chain variable (VH) domain comprising a complementarity determining region (CDR) 1 of SEQ ID NO: 22, a CDR2 of SEQ ID NO: 23, and a CDR3 of SEQ ID NO: 24, and a light chain variable (VL) domain comprising a CDR1 of SEQ ID NO: 25, a CDR2 of SEQ ID NO: 26, and a CDR3 of SEQ ID NO: 27;

a first WASp signature peptide of WAS having the sequence of SEQ ID NO: 2 with an antibody or antigen-binding fragment thereof that binds the first WASp signature peptide and comprises: a VH domain comprising a CDR1 of SEQ ID NO: 28, a CDR2 of SEQ ID NO: 29, and a CDR3 of SEQ ID NO: 30, and a VL domain comprising a CDR1 of SEQ ID NO: 31, a CDR2 of SEQ ID NO: 32, and a CDR3 of SEQ ID NO: 33; and

a BTK signature peptide of XLA having the sequence of SEQ ID NO: 4 with an antibody or antigen-binding fragment thereof that binds the first BTK signature peptide and comprises: a VH domain comprising a CDR1 of SEQ ID NO: 34, a CDR2 of SEQ ID NO: 35, and a CDR3 of sequence GDI, and a VL domain comprising a CDR1 of SEQ ID NO: 36, a CDR2 of SEQ ID NO: 37, and a CDR3 of SEQ ID NO: 38; and performing liquid chromatography-multiple reaction monitoring mass spectrometry (LC-MRM-MS) on the enriched peptides to determine a concentration for each signature peptide, thereby detecting signature peptides of SCID, WAS, and XLA in the DBS sample.

2. The method of claim 1 , wherein the method further comprises detecting signature peptides of cystinosis by enriching for:

a first cystinosin (CTNS) signature peptide of cystinosis having the sequence of SEQ ID NO: 6 with an antibody or antigen-binding fragment thereof that binds the first CTNS signature peptide and comprises: a VH domain comprising a CDR1 of SEQ ID NO: 39, a CDR2 of SEQ ID NO: 40, and a CDR3 of SEQ ID NO: 41, and a VL domain comprising a CDR1 of SEQ ID NO: 42, a CDR2 of SEQ ID NO: 43, and a CDR3 of SEQ ID NO: 44;

a second CTNS signature peptide of cystinosis having the sequence of SEQ ID NO: 7 or 8 with an antibody or antigen-binding fragment thereof that binds the second CTNS signature peptide and comprises: a VH domain comprising a CDR1 of SEQ ID NO: 45, a CDR2 of SEQ ID NO: 46, and a CDR3 of SEQ ID NO: 47, and a VL domain comprising a CDR1 of SEQ ID NO: 48, a CDR2 of SEQ ID NO: 49, and a CDR3 of SEQ ID NO: 50;

a SHPK signature peptide of cystinosis having the sequence of SEQ ID NO: 9 with an antibody or antigen-binding fragment thereof that binds the first SHPK signature peptide and comprises: a VH domain comprising a CDR1 of SEQ ID NO: 51, a CDR2 of SEQ ID NO: 52, and a CDR3 of SEQ ID NO: 53, and a VL domain comprising aCDR1 of SEQ ID NO: 54, a CDR2 of SEQ ID NO: 55, and a CDR3 of SEQ ID NO: 56; and

performing liquid chromatography-multiple reaction monitoring mass spectrometry (LC-MRM-MS) on the enriched first CTNS signature peptide, the enriched second CTNS signature peptide, the enriched SHPK signature peptide to determine a concentration for each signature peptide, thereby detecting signature peptides of cystinosis.

3. The method of claim 2 , wherein the method further comprises detecting signature peptides of Wilson Disease (WD) by enriching for:

an ATP7B signature peptide of WD having the sequence of SEQ ID NO: 11 or 21 with an antibody or antigen-binding fragment thereof that binds the ATP7B signature peptide and comprises: a VH domain comprising a CDR1 of SEQ ID NO: 57, a CDR2 of SEQ ID NO: 58, and a CDR3 of SEQ ID NO: 59, and a VL domain comprising a CDR1 of SEQ ID NO: 60, a CDR2 of SEQ ID NO: 61, and a CDR3 of SEQ ID NO: 62; and

performing liquid chromatography-multiple reaction monitoring mass spectrometry (LC-MRM-MS) on the enriched ATP7B signature peptide, to determine a concentration for the signature peptide, thereby detecting signature peptides of WD.

4. The method of claim 3 , further comprising comparing the concentration of each signature peptide to that of a corresponding predetermined threshold concentration.

5. The method of claim 4 , further comprising diagnosing the subject with:

SCID when the concentration of the CD3ε signature peptide is lower than a predetermined threshold concentration or when the CD3ε signature peptide is absent;

WAS when the concentration of the first WASp signature peptide is lower than corresponding predetermined threshold concentration or when the first WASp signature peptide is absent;

XLA when the concentration of the BTK signature peptide is lower than corresponding predetermined threshold concentration or when the first BTK signature peptide is absent;

cystinosis when the concentrations of the first CTNS and/or the second CTNS signature peptides are lower than corresponding predetermined threshold concentrations or when the first CTNS, the second CTNS, and/or the SHPK peptides are absent; and/or

WD when the concentration of the ATP7B-signature peptides is lower than corresponding predetermined threshold concentration or when the ATP7B signature peptides is absent.

6. The method of claim 4 , wherein the corresponding predetermined threshold concentration for each signature peptide is calculated from a standard deviation of a mean concentration of each signature peptide in DBS from a population of normal control subjects.

7. The method of claim 6 , wherein a mean concentration of the CD3ε signature peptide of SCID having the sequence of SEQ ID NO: 1 in DBS from a population of normal control subjects comprises a concentration in a range of 70 pmol/L to 400 pmol/L.

8. The method of claim 6 , wherein a mean concentration of the first WASp signature peptide of WAS having the sequence of SEQ ID NO: 2 in DBS from a population of normal control subjects comprises a concentration in a range of 600 pmol/L to 5000 pmol/L.

9. The method of claim 6 , wherein a mean concentration of the BTK signature peptide of XLA having the sequence of SEQ ID NO: 4 in DBS from a population of normal control subjects comprises a concentration in a range of 350 pmol/L to 2500 pmol/L.

10. The method of claim 6 , wherein a mean concentration of the first CTNS signature peptide of cystinosis having the sequence of SEQ ID NO: 6 in DBS from a population of normal control subjects comprises a concentration in a range of 40 pmol/L to 250 pmol/L.

11. The method of claim 6 , wherein a mean concentration of the SHPK signature peptide of cystinosis having the sequence of SEQ ID NO: 9 in DBS from a population of normal control subjects comprises a concentration in a range of 100 pmol/L to 8000 pmol/L.

12. The method of claim 6 , wherein a mean concentration of the ATP7B signature peptide of WD having the sequence of SEQ ID NO: 11 or 21 in DBS from a population of normal control subjects comprises a concentration in a range of 90 pmol/L to 400 pmol/L.

13. An assay for screening severe combined immunodeficiency (SCID), Wiskott-Aldrich syndrome (WAS), and/or X-linked agammaglobulinemia (XLA) in a subject, the assay comprising: (i) (A) an antibody or antigen-binding fragment thereof comprising: a heavy chain variable (VH) domain comprising a complementarity determining region (CDR) 1 of SEQ ID NO: 22, a CDR2 of SEQ ID NO: 23, and a CDR3 of SEQ ID NO: 24, and a light chain variable (VL) domain comprising a CDR1 of SEQ ID NO: 25, a CDR2 of SEQ ID NO: 26, and a CDR3 of SEQ ID NO: 27;

an antibody or antigen-binding fragment thereof comprising: a VH domain comprising a CDR1 of SEQ ID NO: 28, a CDR2 of SEQ ID NO: 29, and a CDR3 of SEQ ID NO: 30, and a VL domain comprising a CDR1 of SEQ ID NO: 31, a CDR2 of SEQ ID NO: 32, and a CDR3 of SEQ ID NO: 33;

an antibody or antigen-binding fragment thereof that binds a WASp signature peptide of WAS having the sequence of SEQ ID NO: 3; and

an antibody or antigen-binding fragment thereof comprising: a VH domain comprising a CDR1 of SEQ ID NO: 34, a CDR2 of SEQ ID NO: 35, and a CDR3 of sequence GDI, and a VL domain comprising a CDR1 of SEQ ID NO: 36, a CDR2 of SEQ ID NO: 37, and a CDR3 of SEQ ID NO: 38; or

(B) the antibody or antigen-binding fragment thereof comprising: a VH domain comprising a CDR1 of SEQ ID NO: 22, a CDR2 of SEQ ID NO: 23, and a CDR3 of SEQ ID NO: 24, and a VL domain comprising a CDR1 of SEQ ID NO: 25, a CDR2 of SEQ ID NO: 26, and a CDR3 of SEQ ID NO: 27;

the antibody or antigen-binding fragment thereof comprising: a VH domain comprising a CDR1 of SEQ ID NO: 28, a CDR2 of SEQ ID NO: 29, and a CDR3 of SEQ ID NO: 30, and a VL domain comprising a CDR1 of SEQ ID NO: 31, a CDR2 of SEQ ID NO: 32, and a CDR3 of SEQ ID NO: 33; and the antibody or antigen-binding fragment thereof comprising: a VH domain comprising a CDR1 of SEQ ID NO: 34, a CDR2 of SEQ ID NO: 35, and a CDR3 of sequence GDI, and a VL domain comprising a CDR1 of as set forth in SEQ ID NO: 36, a CDR2 of SEQ ID NO: 37, and a CDR3 of SEQ ID NO: 38; and

(ii) reference signature peptides comprising:

a CD3ε peptide of SCID having the sequence of SEQ ID NO: 1;

a WASp peptide of WAS having the sequence of SEQ ID NO: 2;

a WASp peptide of WAS having the sequence of SEQ ID NO: 3;

a BTK peptide of XLA having the sequence of SEQ ID NO: 4; and/or

a BTK peptide of XLA having the sequence of SEQ ID NO: 5.

14. The assay of claim 13 to further screen for cystinosis, the assay further comprising: (iii) an antibody or antigen-binding fragment thereof comprising:

a VH domain comprising a CDR1 of SEQ ID NO: 39, a CDR2 of SEQ ID NO: 40, and a CDR3 of SEQ ID NO: 41, and a VL domain comprising a CDR1 of SEQ ID NO: 42, a CDR2 of SEQ ID NO: 43, and a CDR3 of SEQ ID NO: 44;

a VH domain comprising a CDR1 of SEQ ID NO: 45, a CDR2 of SEQ ID NO: 46, and a CDR3 of SEQ ID NO: 47, and a VL domain comprising a CDR1 of SEQ ID NO: 48, a CDR2 of SEQ ID NO: 49, and a CDR3 of SEQ ID NO: 50; and/or

a VH domain comprising a CDR1 of SEQ ID NO: 51, a CDR2 of SEQ ID NO: 52, and a CDR3 of SEQ ID NO: 53, and a VL domain comprising a CDR1 of SEQ ID NO: 54, a CDR2 of SEQ ID NO: 55, and a CDR3 of SEQ ID NO: 56; and/or (iv) reference signature peptides comprising:

a CTNS peptide of cystinosis having the sequence of SEQ ID NO: 6;

a CTNS peptide of cystinosis having the sequence of SEQ ID NO: 7 or 8;

a CTNS peptide of cystinosis having the sequence of SEQ ID NO: 12;

a CTNS peptide of cystinosis having the sequence of SEQ ID NO: 13;

a SHPK peptide of cystinosis having the sequence of SEQ ID NO: 9;

a SHPK peptide of cystinosis having the sequence of SEQ ID NO: 14; and/or

a SHPK peptide of cystinosis having the sequence of SEQ ID NO: 15.

15. The assay of claim 14 to further screen for Wilson Disease, the assay further comprising:

(v) an antibody or antigen-binding fragment thereof comprising: a VH domain comprising a CDR1 of SEQ ID NO:57, of SEQ ID NO: 58, and a CDR3 of SEQ ID NO: 59, and a VL domain comprising a CDR1 of SEQ ID NO: 60, a CDR2 of SEQ ID NO: 61, and a CDR3 of SEQ ID NO: 62; and/or

(vi) reference signature peptides comprising:

an ATP7B peptide of WD having the sequence of SEQ ID NO: 10;

an ATP7B peptide of WD having the sequence of SEQ ID NO: 11;

an ATP7B peptide of WD having the sequence of SEQ ID NO: 16;

an ATP7B peptide of WD having the sequence of SEQ ID NO: 17;

an ATP7B peptide of WD having the sequence of SEQ ID NO: 18;

an ATP7B peptide of WD having the sequence of SEQ ID NO: 19;

an ATP7B peptide of WD having the sequence of SEQ ID NO: 20; and/or

an ATP7B peptide of WD having the sequence of SEQ ID NO: 21.

16. A recombinant antibody or antigen binding fragment thereof, wherein:

(A) a variable heavy (VH) domain comprises a complementary determining region (CDR) 1 of SEQ ID NO: 22, a CDR2 of SEQ ID NO: 23, and a CDR3 of SEQ ID NO: 24, and a variable light (VL) domain comprises a CDR1 of SEQ ID NO: 25, a CDR2 of SEQ ID NO: 26, and a CDR3 of SEQ ID NO: 27;

(B) a VH domain comprises a CDR1 of SEQ ID NO: 28, a CDR2 of SEQ ID NO: 29, and a CDR3 of SEQ ID NO: 30, and a VL domain comprises a CDR1 of SEQ ID NO: 31, a CDR2 of SEQ ID NO: 32, and a CDR3 of SEQ ID NO: 33;

(C) a VH domain comprises a CDR1 of SEQ ID NO: 34, a CDR2 of SEQ ID NO: 35, and a CDR3 of sequence GDI, and a VL domain comprises a CDR1 of SEQ ID NO: 36, a CDR2 of SEQ ID NO: 37, and a CDR3 of SEQ ID NO: 38;

(D) a VH domain comprises a CDR1 of SEQ ID NO: 39, a CDR2 of SEQ ID NO: 40, and a CDR3 of SEQ ID NO: 41, and a VL domain comprises a CDR1 of SEQ ID NO: 42, a CDR2 of SEQ ID NO: 43, and a CDR3 of SEQ ID NO: 44;

(E) a VH domain comprises a CDR1 of SEQ ID NO: 45, a CDR2 of SEQ ID NO: 46, and a CDR3 of SEQ ID NO: 47, and a VL domain comprises a CDR1 of SEQ ID NO: 48, a CDR2 of SEQ ID NO: 49, and a CDR3 of SEQ ID NO: 50;

(F) a VH domain comprises a CDR1 of SEQ ID NO: 51, a CDR2 of SEQ ID NO: 52, and a CDR3 of SEQ ID NO: 53, and a VL domain comprises a CDR1 of SEQ ID NO: 54, a CDR2 of SEQ ID NO: 55, and a CDR3 of SEQ ID NO: 56; or

(G) a VH domain comprises a CDR1 of SEQ ID NO: 57, a CDR2 of SEQ ID NO: 58, and a CDR3 of SEQ ID NO: 59, and a VL domain comprises a CDR1 of SEQ ID NO: 60, a CDR2 of SEQ ID NO: 61, and a CDR3 of SEQ ID NO: 62, each according to Kabat numbering.

Assignments (4)
CONFIRMATORY LICENSE Recorded Dec 4, 2023
From: SEATTLE CHILDREN'S HOSPITAL
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 065762/0435 →
MERGER AND CHANGE OF NAME Recorded Dec 19, 2022
From: FRED HUTCHINSON CANCER RESEARCH CENTER; SEATTLE CANCER CARE ALLIANCE
To: FRED HUTCHINSON CANCER CENTER
Reel/Frame 062145/0694 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 7, 2021
From: HAHN, SIHOUN; JUNG, SUNHEE; TORGERSON, TROY; COLLINS, CHRISTOPHER; DAYUHA, REMWILYN
To: SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE
Reel/Frame 055858/0520 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 7, 2021
From: WHITEAKER, JEFFREY; PAULOVICH, AMANDA
To: FRED HUTCHINSON CANCER RESEARCH CENTER
Reel/Frame 055858/0540 →
Continuity (2)
Provisional Application 62742161 · Oct 5, 2018
Related Publication 20210341492A1 · Nov 4, 2021
References Cited (154)
US 7632686B2 · Anderson · 2009 [cited by applicant]
US 8383417B2 · Lopez et al. · 2013 [cited by applicant]
US 9588126B2 · Anderson · 2017 [cited by applicant]
US 10590190B2 · Rosenthal et al. · 2020 [cited by applicant]
US 20070099251A1 · Zhang et al. · 2007 [cited by applicant]
US 20070243191A1 · Mao et al. · 2007 [cited by applicant]
US 20070265432A1 · Meikle et al. · 2007 [cited by applicant]
US 20100003239A1 · Scales · 2010 [cited by applicant]
US 20100009463A1 · Hornbeck et al. · 2010 [cited by applicant]
US 20110217790A1 · Pass et al. · 2011 [cited by applicant]
US 20120156710A1 · Nakayama et al. · 2012 [cited by applicant]
US 20120184050A1 · Meikle et al. · 2012 [cited by applicant]
US 20120225060A1 · Lee et al. · 2012 [cited by applicant]
US 20130105684A1 · Louette et al. · 2013 [cited by applicant]
US 20130137595A1 · Zangar et al. · 2013 [cited by applicant]
US 20130302399A1 · Feldhaus et al. · 2013 [cited by applicant]
US 20140106981A1 · Hood et al. · 2014 [cited by applicant]
US 20140273275A1 · Jacobs et al. · 2014 [cited by applicant]
US 20150322423A1 · Kosugi et al. · 2015 [cited by applicant]
US 20160083458A1 · Katsuragi et al. · 2016 [cited by applicant]
US 20160319005A1 · Lopez-Girona et al. · 2016 [cited by applicant]
US 20180086846A1 · Wiltzius et al. · 2018 [cited by applicant]
US 20180164301A1 · Anderson · 2018 [cited by applicant]
US 20190031754A1 · Rader et al. · 2019 [cited by applicant]
US 20190134164A1 · DeRosa et al. · 2019 [cited by applicant]
US 20210285965A1 · Hahn et al. · 2021 [cited by applicant]
US 20210302435A1 · Hahn et al. · 2021 [cited by applicant]
US 20230194545A1 · Hahn · 2023 [cited by applicant]
US 20240248096A1 · Hahn et al. · 2024 [cited by applicant]
CN 1367830A · 2002 [cited by applicant]
CN 1635908A · 2005 [cited by applicant]
EP 2072527A1 · 2009 [cited by applicant]
JP WO2014037977A1 · 2014 [cited by applicant]
WO WO2009033743A1 · 2009 [cited by examiner]
WO WO2011015602A2 · 2011 [cited by applicant]
WO WO2013106603A1 · 2013 [cited by applicant]
WO WO2013148284A1 · 2013 [cited by applicant]
WO 2016110584A1 · 2016 [cited by applicant]
WO WO2017062672A2 · 2017 [cited by applicant]
WO WO2017106292A2 · 2017 [cited by applicant]
WO WO2018097951A1 · 2018 [cited by applicant]
WO WO2019030377A1 · 2019 [cited by applicant]
WO WO2019126647A1 · 2019 [cited by applicant]
WO WO2019149816A1 · 2019 [cited by applicant]
WO WO2019173291A1 · 2019 [cited by applicant]
WO WO2021178545A1 · 2021 [cited by applicant]
Mariuzza (Annu. Rev. Biophys. Biophys. Chem., 16: 139-159, 1987) (Year: 1987). [cited by examiner]
McCarthy et al. (J. Immunol. Methods, 251(1-2): 137-149, 2001) (Year: 2001). [cited by examiner]
Lin et al. (African Journal of Biotechnology, 10(79):18294-18302, 2011) (Year: 2011). [cited by examiner]
Chinese Office Action mailed Dec. 8, 2023 for Chinese Application No. 201980065851.5, a foreign counterpart to U.S. Appl. No. 17/282,989, 18 pages. [cited by applicant]
Japanese Office Action mailed Oct. 10, 2023 for Japanese Application No. 2021-518442, a foreign counterpart to U.S. Appl. No. 17/282,989, 7 pages. [cited by applicant]
Office Action for Japan Application No. 2021-518442, issued Jul. 9, 2024, 6pp. [cited by applicant]
Almannai, et al., “Newborn screening: a review of history, recent advancements, and future perspectives in the era of next generation sequencing,” Current Opinion in Pediatrics, vol. 28, No. 6, 2016, pp. 694-699. [cited by applicant]
Anderson, et al., “Mass spectrometric quantitation of peptides and proteins using Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA),” Journal of Proteome Research, vol. 3, No. 2, 2004, pp. 235-24… [cited by applicant]
Anderson, et al., “SISCAPA peptide enrichment on magnetic beads using an in-line bead trap device,” Molecular & Cellular Proteomics, vol. 8, No. 5, 2009, pp. 995-1005. [cited by applicant]
Beynon, et al., “Multiplexed absolute quantification in proteomics using artificial QCAT proteins of concatenated signature peptides,” Nature Methods, vol. 2, No. 8, 2005, pp. 587-589. [cited by applicant]
Brun, et al., “Isotope-labeled Protein Standards: Toward Absolute Quantitative Proteomics,” Molecular & Cellular Proteomics, vol. 6, No. 12, 2007, pp. 2139-2149. [cited by applicant]
Carroll, et al., “Absolute quantification of the glycolytic pathway in yeast: deployment of a complete QconCAT approach,” Molecular & Cellular Proteomics, vol. 10, No. 12, 2011, 15 pages. [cited by applicant]
Chace & Kalas, “A biochemical perspective on the use of tandem mass spectrometry for newborn screening and clinical testing,” Clinical Biochemistry, vol. 38, No. 4, 2005, pp. 296-309. [cited by applicant]
Chase, et al., “Mass spectrometry in newborn and metabolic screening: historical perspective and future directions,” Journal of Mass Spectrometry, vol. 44, No. 2, 2009, pp. 163-170. [cited by applicant]
Chase, et al., “Rapid diagnosis of phenylketonuria by quantitative analysis for phenylalanine and tyrosine in neonatal blood spots by tandem mass spectrometry,” Clinical Chemistry, vol. 39, No. 1, 1993, pp. 66-71. [cited by applicant]
Cutillas, “Principles of Nanoflow Liquid Chromatography and Applications to Proteomics,” Current Nanoscience, vol. 1, No. 1, 2005, pp. 65-71. [cited by applicant]
Ding, et al., “Quantitative analysis of cohesin complex stoichiometry and SMC3 modification-dependent protein Interactions,” Journal of Proteome Research, vol. 10, No. 8, 2011, pp. 3652-3659. [cited by applicant]
Dott, et al., “Metabolic disorders detectable by tandem mass spectrometry and unexpected early childhood mortality: a population-based study,” American Journal of Medical Genetics Part A, vol. 140, No. 8, 2006, pp. 837-… [cited by applicant]
Gerber, et al., “Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS,” PNAS USA, vol. 100, No. 12, 2003, pp. 6940-6945. [cited by applicant]
Holman, et al., “The use of selected reaction monitoring in quantitative proteomics,” Bioanalysis, vol. 4, No. 14, 2012, pp. 1763-1786. [cited by applicant]
Holzmann, et al., “Stoichiometry determination of the MP1-p14 complex using a novel and cost-efficient method to produce an equimolar mixture of standard peptides,” Analytical Chemistry, vol. 81, No. 24, 2009, pp. 10254… [cited by applicant]
Hoofnagle, et al., “Quantification of thyroglobulin, a low-abundance serum protein, by immunoaffinity peptide enrichment and tandem mass spectrometry,” Clinical Chemistry, vol. 54, No. 11, 2008, pp. 1796-1804. [cited by applicant]
Hoofnagle, et al., “Recommendations for the Generation, Quantification, Storage, and Handling of Peptides Used for Mass Spectrometry-Based Assays” Clinical Chemistry, vol. 62, No. 1, 2016, pp. 48-69. [cited by applicant]
Johnson, et al., “Rigorous determination of the stoichiometry of protein phosphorylation using mass spectrometry,” Journal of the American Society for Mass Spectrometry, vol. 20, No. 12, 2009, pp. 2211-2220. [cited by applicant]
Kennedy, et al., “Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins,” Nature Methods, vol. 11, No. 2, 2014, pp. 149-155. [cited by applicant]
Kirkpatrick, et al., “The absolute quantification strategy: a general procedure for the quantification of proteins and post-translational modifications,” Methods, vol. 35, No. 3, 2005, pp. 265-273. [cited by applicant]
Kito, et al., “A synthetic protein approach toward accurate mass spectrometric quantification of component stoichiometry of multiprotein complexes,” Journal of Proteome Research, vol. 6, No. 2, 2007, pp. 792-800. [cited by applicant]
Kuhn, et al., “Developing Multiplexed Assays for Troponin I and Interleukin-33 in Plasma by Peptide Immunoaffinity Enrichment and Targeted Mass Spectrometry” Clinical Chemistry, vol. 55, No. 6, 2009, pp. 1108-1117. [cited by applicant]
Lange, et al., “Selected reaction monitoring for quantitative proteomics: a tutorial,” Molecular Systems Biology, vol. 4, No. 1, 2008, 14 pages. [cited by applicant]
Lundgren, et al., “Role of spectral counting in quantitative proteomics,” Expert Review of Proteomics, vol. 7, No. 1, 2010, pp. 39-53. [cited by applicant]
Mallick, et al., “Computational prediction of proteotypic peptides for quantitative proteomics,” Nature Biotechnology, vol. 25, 2007, pp. 125-131. [cited by applicant]
Millington, et al., “Tandem mass spectrometry: a new method for acylcarnitine profiling with potential for neonatal screening for inborn errors of metabolism,” Journal of Inherited Metabolic Disease, vol. 13, 1990, pp. … [cited by applicant]
Nelson, et al., “Mass spectrometric immunoassay,” Analytical Chemistry, vol. 67, No. 7, 1995, pp. 1153-1158. [cited by applicant]
PCT Search Report and Written Opinion mailed on Jun. 4, 2021 for PCT Application No. PCT/US2021/0206797, 26 pages. [cited by applicant]
Sweetman, et al., “Naming and counting disorders (conditions) included in newborn screening panels,” Pediatrics, vol. 117, No. 5, 2006, pp. S308-S314. [cited by applicant]
Watson, et al., “Main Report,” Genetics in Medicine, vol. 8, No. 5, 2006, pp. 12S-252S. [cited by applicant]
Whiteaker & Paulovich, “Peptide immunoaffinity enrichment coupled with mass spectrometry for peptide and protein quantification” Clinics in Laboratory Medicine, vol. 31, No. 3, 2011, pp. 385-396. [cited by applicant]
Whiteaker, et al., “An automated and multiplexed method for high throughput peptide immunoaffinity enrichment and multiple reaction monitoring mass spectrometry-based quantification of protein biomarkers,” Molecular & C… [cited by applicant]
Zhao, et al., “Quantification of proteins using peptide immunoaffinity enrichment coupled with mass spectrometry,” Journal of Visualized Experiments, vol. 53, 2011, 5 pages. [cited by applicant]
Roos, et al., “X-CGDbase: a database of X-CGD-causing mutations”, Immunology Today, vol. 17, Issue 11, Nov. 1996, pp. 517-521. [cited by applicant]
Schmalstieg, et al., “Effect of RBC Transfusions on Adenosine Deaminase(ADA) Deficient Severe Combined Immunodeficiency(SCID),” Pediatric Research, vol. 11, No. 4, 1977, 1 page. [cited by applicant]
Partial European Search Report for European Application No. 21780186.9, Dated Apr. 29, 2024, 13 pages. [cited by applicant]
Staal, et al., “Autologous Stem-Cell-Based Gene Therapy for Inherited Disorders: State of the Art and Perspectives,” Frontiers in Pediatrics, vol. 7, No. 443, 2019, 9 pages. [cited by applicant]
Tangye, et al., “Human Inborn Errors of Immunity: 2019 Update on the Classification from the International Union of Immunological Societies Expert Committee,” Journal of Clinical Immunology, vol. 40, 2020, pp. 24-64. [cited by applicant]
United States Centers for Disease Control and Prevention, “Interim Guidelines for Collecting and Handling of Clinical Specimens for COVID-19 Testing,” retrieved on Apr. 22, 2021 at <<https://www.cdc.gov/coronavirus/2019… [cited by applicant]
Whiteaker, et al., “High-affinity recombinant antibody fragments (Fabs) can be applied in peptide enrichment immuno-MRM assays,” Journal of Proteome Research, vol. 13, No. 4, 2014, pp. 2187-2196. [cited by applicant]
Whitmore & Gaspar, “Adenosine Deaminase Deficiency—More Than Just an Immunodeficiency,” Frontiers in Immunology, vol. 7, No. 314, 2016, 13 pages. [cited by applicant]
Zhou, et al., “Impact of human granulocyte and monocyte isolation procedures on functional studies,” Clinical and Vaccine Immunology, vol. 19, 7, 2012, pp. 1065-1074. [cited by applicant]
“Buccal Swab Collection Procedure,” retrieved on Apr. 22, 2021 at <<https://www.chla.org/sites/default/files/atoms/files/CHLA-Clinical-Pathology-Buccal-Swab-Collection-Procedure.pdf>>, 1 page. [cited by applicant]
America & Cordewener, “Comparative LC-MS: A landscape of peaks and valleys,” Bioinformatics, vol. 8, No. 4, 2008, pp. 731-749. [cited by applicant]
Anderson & Hunter, “Quantitative Mass Spectrometric Multiple Reaction Monitoring Assays for Major Plasma Proteins,” Molecular & Cellular Proteomics, vol. 5, No. 4, 2006, pp. 573-588. [cited by applicant]
Aydin, et al., “DOCK8 deficiency: clinical and immunological phenotype and treatment options—a review of 136 patients,” Journal of Clinical Immunology, vol. 35, No. 2, 2015, 10 pages. [cited by applicant]
Baker, et al., “Development of a routine newborn screening protocol for severe combined immunodeficiency,” The Journal of Allergy and Clinical Immunology, vol. 124, No. 3, 2009, pp. 522-527. [cited by applicant]
Baron, et al., “Epigenetic immune cell counting in human blood samples for immunodiagnostics,” Science Translational Medicine, vol. 10, No. 452, 2018, 12 pages. [cited by applicant]
BD Biosciences, “BD Vacutainer(CR) CPT(TM) Mononuclear Cell Preparation Tube—Sodium Citrate,” retrieved on May 6, 2021 at <<https://www.bdbiosciences.com/us/applications/blood-collection/cell-biomarker-preservation/bd-v… [cited by applicant]
Bonilla, et al., “Practice parameter for the diagnosis and management of primary immunodeficiency,” The Journal of Allergy and Clinical Immunology, vol. 136, No. 5, 2015, pp. 1186-1205.E78. [cited by applicant]
Booth & Gaspar, “Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID),” Biologics, vol. 3, 2009, pp. 349-358. [cited by applicant]
Chan & Puck, “Development of population-based newborn screening for severe combined immunodeficiency,” The Journal of Allergy and Clinical Immunology, vol. 115, No. 2, 2005, pp. 391-398. [cited by applicant]
Chase, et al., “Newborn screening for T-cell deficiency,” Current Opinion in Allergy and Clinical Immunology, vol. 10, No. 6, 2010, pp. 521-525. [cited by applicant]
Chen, et al., “Development of a Multiplexed Liquid Chromatography Multiple-Reaction-Monitoring Mass Spectrometry (LC-MRM/MS) Method for Evaluation of Salivary Proteins as Oral Cancer Biomarkers”, Molecular & Cellular Pr… [cited by applicant]
Collins, et al., “Multiplexed Proteomic Analysis for Diagnosis and Screening of Five Primary Immunodeficiency Disorders From Dried Blood Spots,” Frontiers in Immunology, vol. 11, No. 464, 2020, 16 pages. [cited by applicant]
Collins, et al., “Rapid Multiplexed Proteomic Screening for Primary Immunodeficiency Disorders From Dried Blood Spots,” Frontiers in Immunology, vol. 9, 2018, 17 pages. [cited by applicant]
Corkum, et al., “Immune cell subsets and their gene expression profiles from human PBMC isolated by Vacutainer Cell Preparation Tube (CP[TM]) and standard density gradient,” BMC Immunology, vol. 16, No. 48, 2015, 18 pag… [cited by applicant]
De Saint Basile, et al., “Severe combined immunodeficiency caused by deficiency in either the delta or the epsilon subunit of CD3,” Journal of Clinical Investigation, vol. 114, No. 10, 2004, pp. 1512-1517. [cited by applicant]
Engelhardt, et al., “Large deletions and point mutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome,” The Journal of Allergy and Clinical Immunology, vol. 124,… [cited by applicant]
Search Report and Written Opinion for European Application No. 21764238.8, Dated Jun. 17, 2024, 14 pages. [cited by applicant]
Search Report and Written Opinion for European Application No. 21780186.9, Dated Jul. 22, 2024, 10 pages. [cited by applicant]
Search Report and Written Opinion for European Application No. 21779339.7, Dated Jul. 8, 2024, 12 pages. [cited by applicant]
Espinosa-de Aquino, et al., “Protein and RNA extraction from mucosal swabs: a minimally invasive source of ecological data for studies of natural populations,” Methods in Ecology and Evolution, vol. 8, No. 3, 2017, pp. … [cited by applicant]
Fargo, et al., “Erythrocyte adenosine deaminase: diagnostic value for Diamond-Blackfan anaemia,” British Journal of Haematology, vol. 160, No. 4, 2013, pp. 547-554. [cited by applicant]
Ferrua, et al., “Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study,” Lancet Haematology, vol. … [cited by applicant]
Flinn & Gennery, “Adenosine deaminase deficiency: a review,” Orphanet Journal of Rare Diseases, vol. 13, No. 1, 2018, 7 pages. [cited by applicant]
Gaspar, et al., “How I treat ADA deficiency,” Blood, vol. 114, No. 17, 2009, pp. 3524-3532. [cited by applicant]
Grievink, et al., “Comparison of Three Isolation Techniques for Human Peripheral Blood Mononuclear Cells: Cell Recovery and Viability, Population Composition, and Cell Functionality,” Biopreservation and Biobanking, vol… [cited by applicant]
Grunebaum, et al., “Bone marrow transplantation for severe combined immune deficiency,” JAMA, vol. 295, No. 5, 2006, pp. 508-518. [cited by applicant]
Jia, et al., “A Modified Ficoll-Paque Gradient Method for Isolating Mononuclear Cells from the Peripheral and Umbilical Cord Blood of Humans for Biobanks and Clinical Laboratories,” Biopreservation and Biobanking, vol. … [cited by applicant]
Jin, et al., “Mutations of the Wiskott-Aldrich Syndrome Protein (WASP): hotspots, effect on transcription, and translation and phenotype/genotype correlation,” Blood, vol. 104, No. 13, 2004, pp. 4010-4019. [cited by applicant]
Jing, et al., “Somatic reversion in dedicator of cytokinesis 8 immunodeficiency modulates disease phenotype,” The Journal of Allergy and Clinical Immunology, vol. 133, No. 6, 2014, pp. 1667-1675. [cited by applicant]
Kanariou, et al., “Long-term observational studies of chronic granulomatous disease,” Current Opinion in Hematology, vol. 25, No. 1, 2018, pp. 7-12. [cited by applicant]
Kaveri, et al., “Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy,” Clinical and Experimental Immunology, vol. 164, No. 2, 2011, pp. 2-5. [cited by applicant]
Kobrynski, et al., “Prevalence and morbidity of primary immunodeficiency diseases, United States 2001-2007,” Journal of Clinical Immunology, vol. 34, No. 8, 2014, pp. 954-961. [cited by applicant]
Kwan, et al., “Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States,” JAMA, vol. 312, No. 7, 2014, pp. 729-738. [cited by applicant]
La Marca, et al., “Diagnosis of immunodeficiency caused by a purine nucleoside phosphorylase defect by using tandem mass spectrometry on dried blood spots,” Journal of Allergy and Clinical Immunology, vol. 134, No. 1, 2… [cited by applicant]
La Marca, et al., “Tandem mass spectrometry, but not T-cell receptor excision circle analysis, identifies newborns with late-onset adenosine deaminase deficiency,” Journal of Allergy and Clinical Immunology, vol. 131, N… [cited by applicant]
La Marca, et al., “The inclusion of ADA-SCID in expanded newborn screening by tandem mass spectrometry,” Journal of Pharmaceutical and Biomedical Analysis, vol. 88, 2014, pp. 201-206. [cited by applicant]
MacCoss Lab Software, “SkyLine,” retrieved on May 6, 2021 at <https://skyline.ms/project/home/begin.view>, MacCoss Lab Software, 2021, 1 page. [cited by applicant]
McCusker, et al., “Primary immunodeficiency,” Allergy, Asthma & Clinical Immunology, vol. 14, No. 2, 2018, 12 pages. [cited by applicant]
Michalczyk, et al., “Fresh and cultured buccal cells as a source of mRNA and protein for molecular analysis,” Bio Techniques, vol. 37, No. 2, 2004, pp. 262-269. [cited by applicant]
Moratto, et al., “Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative stud… [cited by applicant]
Otogenetics Corporation, “Instruction for Buccal Swab Sample Collection,” retrieved on Apr. 22, 2021 at <<https://www.otogenetics.com/wp-content/uploads/2018/01/buccal-swab-collection-instructions.pdf>>, 1 page. [cited by applicant]
Parta, et al., “Allogeneic Reduced-Intensity Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease: a Single-Center Prospective Trial,” Journal of Clinical Immunology, vol. 37, No. 6, 2017, pp. 548-5… [cited by applicant]
Pathway Genomics, “Buccal DNA Collection Instructions,” retrieved on Apr. 22, 2021 at <<https://www.pathway.com/wp-content/uploads/2017/06/Buccal-Swab-Collection-Instructions.pdf>>, 1 page. [cited by applicant]
PersonalizeDx Labs, “Buccal Swab collection procedure,” Youtube uploaded by PersonalizeDx Labs, Nov. 28, 2017, https://www.youtube.com/watch?v=3ftvHkfM710&t=152s, 4 pages. [cited by applicant]
Puleo, et al., “Isolation of Peripheral Blood Mononuclear Cells Using Vacutainer“CR” Cellular Preparation Tubes (CPTTM),” Bio-Protocol, vol. 7, No. 2, 2017, 6 pages. [cited by applicant]
Qasim, et al., “Protein assays for diagnosis of Wiskott-Aldrich syndrome and X-linked thrombocytopenia,” British Journal of Haematology, vol. 113, No. 4, 2001, pp. 861-865. [cited by applicant]
Raje & Dinakar, “Overview of Immunodeficiency Disorders,” Immunology and Allergy Clinics of North America, vol. 35, No. 4, 2015, pp. 599-623. [cited by applicant]
De Mello et al. Feasibility of using cryopreserved lymphoblastoid cells to diagnose some lysosomal storage diseases, Cell Proliferation, Feb. 26, 2010 (Feb. 26, 2010). vol. 43, No. 2, pp. 164-169. [cited by applicant]
Invitation to Pay Fees Dated Jul. 13, 2021 in International Application No. PCT/US2021/025627, 3 Pages. [cited by applicant]
Search Report and Written Opinion Dated Jul. 22, 2021 in International Application No. PCT/US2021/025270, 20 pages. [cited by applicant]
Search Report and Written Opinion Dated Sep. 21, 2021 for International Application No. PCT/US2021/025627, 14 pages. [cited by applicant]
Van Doorn et al. “Salivary a-Iduronidase Activity as a Potential New Biomarker for the Diagnosis and Monitoring the Effect of Therapy in Mucopolysaccharidosis Type I,” Biology of Blood and Marrow Transplantation, Sep. 3… [cited by applicant]
Invitation to Pay Addition Fees Dated Dec. 26, 2019 in International Application No. PCT/US2019/054856, 8 pages. [cited by applicant]
Jung, et al., “Quanitification of ATP7B Protein in Dried Blood Spots by Peptide Immuno-SRM as a Potential Screen for Wilson's Disease,” J. Proteome. Res., vol. 16, No. 2, 2017, pp. 862-871. [cited by applicant]
Kerfoot, et al., “Tryptic peptide screening for primary immunodeficiency disease by LC/MS-MS,” Proteomics Clin. Appl, vol. 6, No. 7-8, 2012, pp. 394-402. [cited by applicant]
Search Report & Written Opinion Dated Feb. 21, 2019 in International Application No. PCT/US19/54856, 14 pages. [cited by applicant]
Extended European Search Report mailed Sep. 27, 2022 for European Application No. 19869877.1, 25 pages. [cited by applicant]
Partial European Search Report Dated Jun. 24, 2022 for European Patent Application No. 19869877.1, 28 pages. [cited by applicant]
Whiteaker, et al., “Antibody-based enrichment of peptides on magnetic beads for mass-spectrometry-based quantification of serum biomarkers”, Analytical Biochemistry, vol. 362, Issue 1, Dec. 20, 2006, pp. 44-54. [cited by applicant]